胰高血糖素样肽-1类似物艾塞那肽增加院外心脏骤停后昏迷患者的血糖清除、乳酸清除和心率
该研究为一项双盲随机临床试验的预设事后分析,纳入106例院外心脏骤停后昏迷并接受目标温度管理的成人患者,无论初始心律如何。患者1:1随机接受艾塞那肽17.4 μg或安慰剂输注6小时15分钟,均在持续自主循环恢复后4小时内启动。在用药后最初6小时内,艾塞那肽组血糖下降速度比安慰剂组快17%(95%CI 8.9-25%,p=0.0004),乳酸下降速度快21%(95%CI 6.0-33%,p=0.02),心率增加约10次/分(p<0.0001),对其他血流动力学变量无影响。作者结论认为这些生理效应的临床重要性尚待研究。
要点
- 在院外心脏骤停后昏迷并接受目标温度管理的成人中,艾塞那肽组用药后6小时内血糖下降速度较安慰剂组快17%(95%CI 8.9-25%,p=0.0004)。
- 同一下降期内,艾塞那肽组乳酸下降速度较安慰剂组快21%(95%CI 6.0-33%,p=0.02)。
- 艾塞那肽组心率较安慰剂组增加约10次/分(p<0.0001)。
- 艾塞那肽对平均动脉压及去甲肾上腺素与多巴胺合并剂量等其他血流动力学变量无影响。
- 作者认为上述生理效应的临床重要性尚待研究。
适用人群与场景
- 成人、昏迷、院外心脏骤停后接受目标温度管理的患者,无论初始心律如何,病因推测为心脏性。
- 来自一家三级心脏中心的ICU,为连续样本。
处置流程与药物剂量
- 在持续自主循环恢复后4小时内启动研究药物输注。
- 艾塞那肽(Byetta;Lilly)17.4 μg输注6小时15分钟,或安慰剂。
- 用药后最初6小时内评估乳酸水平、血糖水平、心率、平均动脉压及去甲肾上腺素与多巴胺合并剂量。
研究设计与关键结果
- 研究类型为双盲随机临床试验的预设事后分析,样本量106例,人群为院外心脏骤停后昏迷成人,干预为艾塞那肽17.4 μg输注6小时15分钟 vs 安慰剂。
- 用药后最初6小时内,艾塞那肽组血糖下降速度较安慰剂组快17%(95%CI 8.9-25%,p=0.0004),乳酸下降速度较安慰剂组快21%(95%CI 6.0-33%,p=0.02)。
- 艾塞那肽组心率较安慰剂组增加约10次/分(p<0.0001)。
- 艾塞那肽对其他血流动力学变量无影响。
证据类型、等级与局限
- 证据类型:双盲随机临床试验的预设事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在院外心脏骤停后昏迷患者中,艾塞那肽输注降低血糖、增加乳酸清除并增加心率,这些生理效应的临床重要性尚待研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the effects of the glucagon-like peptide-1 analog exenatide on blood glucose, lactate clearance, and hemodynamic variables in comatose, resuscitated out-of-hospital cardiac arrest patients.
DESIGN: Predefined post hoc analyzes from a double-blind, randomized clinical trial.
SETTING: The ICU of a tertiary heart center.
PATIENTS: Consecutive sample of adult, comatose patients undergoing targeted temperature management after out-of-hospital cardiac arrest from a presumed cardiac cause, irrespective of the initial cardiac rhythm.
INTERVENTIONS: Patients were randomized 1:1 to receive 6 hours and 15 minutes of infusion of either 17.4 μg of the glucagon-like peptide-1 analog exenatide (Byetta; Lilly) or placebo within 4 hours from sustained return of spontaneous circulation. The effects of exenatide were examined on the following prespecified covariates within the first 6 hours from study drug initiation: lactate level, blood glucose level, heart rate, mean arterial pressure, and combined dosage of norepinephrine and dopamine.
MEASUREMENTS AND MAIN RESULTS: The population consisted of 106 patients receiving either exenatide or placebo. During the first 6 hours from study drug initiation, the levels of blood glucose and lactate decreased 17% (95% CI, 8.9-25%; p = 0.0004) and 21% (95% CI, 6.0-33%; p = 0.02) faster in patients receiving exenatide versus placebo, respectively. Exenatide increased heart rate by approximately 10 beats per minute compared to placebo (p < 0.0001). There was no effect of exenatide on other hemodynamic variables.
CONCLUSIONS: In comatose out-of-hospital cardiac arrest patients, infusion with exenatide lowered blood glucose and resulted in increased clearance of lactate as well as increased heart rate. The clinical importance of these physiologic effects remains to be investigated.
参考来源
- Wiberg S, Kjaergaard J, Schmidt H, et al. The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest. Crit Care Med. 2018. PMID: 29189347. doi:10.1097/CCM.0000000000002814
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。